CD19 and B-cell chronic lymphocytic leukemia: In a clinical trial of 18 adults with CD19 + CLL who were heavily pretreated and had recurrent or sustained disease, Porter and colleagues showed that 8 (57%) of the patients responded to autologous CD19 CAR-T cells therapy [113].